Dawex Announces the Launch of the Japan Data Exchange (JDEX) to Foster a New Data Community
30.11.2020 12:00:00 EET | Business Wire | Press release
Dawex, the leading data exchange technology company, today announced with Kanematsu Corporation and Japan Data Exchange Inc. the launch of JDEX, a Data Exchange Platform to create a large data trading community in Japan, spanning across industry, academia, and government, and contribute to the promotion of a cross-industry and cross-border data exchange environment. The platform, relying on Dawex Data Exchange technology and operated by Kanematsu, will serve the multinational trading corporation’s domestic and foreign network. JDEX platform enables the sourcing, exchange, sharing and commercialization of data products leveraging the platform's advanced features and capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005371/en/
JDEX Platform - Login screen (Photo: Dawex)
Emerging as a key component of the data economy, Data Exchanges are now clearly top of the agenda of an increasing number of corporations, public institutions and governments around the world. With new initiatives on frameworks and policies multiplying everywhere such as GAIA-X in Europe, Data Trading Alliance in Japan, the World Economic Forum or the Data Exchange Association (DXA), the market is increasingly being regulated and standardized encouraging the development of trusted cross-border, cross-industry data ecosystems such as JDEX.
Awarded “Technology Pioneer” and chosen for the Global Future Council on Data Policy by the World Economic Forum in June 2020, Dawex delivered to Kanematsu the means to deploy a powerful data exchange strategy and to create value as the orchestrator of a rich data ecosystem in Japan and abroad.
“Developing the Japan Data Exchange (JDEX) is a crucial part of Kanematsu’s data strategy that we initiated three years ago. By partnering with Dawex, we rely on the most advanced data exchange technology available today to create and support a new data community. The flexibility and sophistication of Dawex solution enables us to offer a secure and trusted environment to data providers and data acquirers and easily address their business needs.” said Mr. Masahiro Harada, Senior Executive Officer, Electronics and Devices Division at Kanematsu Corporation.
“We are very excited to see this realization with Kanematsu coming to fruition and to observe the multiplication of cross-border and cross-industry data exchange initiatives. This results from a strong commitment impulsed by the Japanese government through its regulations, and initiatives such as the Osaka Track, enabling JDEX to build a rich data community.” stated Laurent Lafaye co-CEO of Dawex.
“Now armed with advanced data infrastructure relying on Dawex technology, and leveraging a mature governance framework, the Japan Data Exchange will unlock the full potential of a growing data ecosystem and set an example for the transition into a data-driven economy.” says Fabrice Tocco, co-CEO of Dawex. “The data marketplace will enable the development of new data models and foster innovation in a trusted and secure environment.”
About Dawex
Dawex, the leading data exchange technology company and the operator of the largest data marketplace, allows organizations to orchestrate data circulation, by sourcing and exchanging data securely, and in full compliance with regulations. Today 12,000+ organizations from 20+ sectors rely on Dawex Global Data Marketplace and Data Exchange Platform solutions to build their data exchange strategy. In 2020, Dawex is named Technology Pioneer by the World Economic Forum. Created in 2015, Dawex is a tech company with offices in France and Canada, expanding business operations to Asia and the Middle East. www.dawex.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005371/en/
Contact information
Dawex press contact
Charles Parant
press@dawex.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom